Q-omics provides the consensus-scored LINC02875 profile across patient tissues and cancer cell-line models. LINC02875 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC02875 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, LINC02875 RNA expression shows 15,725 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, COAD, and TGCT as cancer lineages where LINC02875 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02875 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02875 survival associations across molecular data types. LINC02875 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02875 RNA expression–survival associations across cancer types. High LINC02875 expression shows unfavorable associations in ACC, LGG and LUAD, but favorable associations in BLCA, UVM and OV. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC02875 RNA expression.
This table summarizes LINC02875 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02875. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02875 shows lower tumor expression in LUAD and UCEC and higher tumor expression in COAD, LIHC, STAD and HNSC. The COAD box plot shows higher LINC02875 RNA expression in tumor versus normal tissue (log2 FC = +0.351, t-test p < 0.001).
This table shows molecular features associated with LINC02875 in patient tissues and cancer cell lines. In patient samples, LINC02875 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC02875 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
